FORM
10-Q
|
x
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Commission
File Number: 0-24249
|
||
PDI,
Inc.
|
||
(Exact
name of registrant as specified in its charter)
|
||
Delaware
|
22-2919486
|
|
(State
or other jurisdiction of Incorporation or organization)
|
(I.R.S
Employer Identification No.)
|
|
Saddle
River Executive Centre
|
||
1
Route 17 South
|
||
Saddle
River, New Jersey 07458
|
||
(Address
of principal executive offices and zip code)
|
||
(201)
258-8450
|
||
(Registrant's
telephone number, including area code)
|
||
Large
accelerated filer £
|
Accelerated
filer £
|
Non-accelerated
filer Q
|
Smaller
reporting company £
|
(Do
not check if a smaller
reporting
company)
|
1.
|
Class
|
Shares
Outstanding
May
1, 2009
|
|
Common
stock, $0.01 par value
|
14,227,909
|
|
PDI,
Inc.
|
|||
Form
10-Q for Period Ended March 31, 2009
|
|||
TABLE
OF CONTENTS
|
|||
Page No.
|
|||
PART
I - FINANCIAL INFORMATION
|
|||
Item
1.
|
Condensed
Consolidated Financial Statements
|
||
Condensed
Consolidated Balance Sheets
at
March 31, 2009 (unaudited) and December 31, 2008
|
3
|
||
Condensed
Consolidated Statements of Operations
for
the three month periods ended March 31, 2009 and 2008
(unaudited)
|
4
|
||
Condensed
Consolidated Statements of Cash Flows
for
the three month periods ended March 31, 2009 and 2008
(unaudited)
|
5
|
||
Notes
to Condensed Consolidated Financial Statements
|
6
|
||
Item
2.
|
Management's
Discussion and Analysis of Financial
Condition
and Results of Operations
|
13
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
18
|
|
Item
4.
|
Controls
and Procedures
|
19
|
|
PART
II - OTHER INFORMATION
|
|||
Item
1.
|
Legal
Proceedings
|
19
|
|
Item
1A.
|
Risk
Factors
|
19
|
|
Item
6.
|
Exhibits
|
20
|
|
Signatures
|
21
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
||||||||
(in
thousands, except share and per share data)
|
||||||||
March
31,
|
December
31,
|
|||||||
2009
|
2008
|
|||||||
(unaudited)
|
||||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 80,931 | $ | 90,074 | ||||
Short-term
investments
|
146 | 159 | ||||||
Accounts
receivable, net
|
9,231 | 15,786 | ||||||
Unbilled
costs and accrued profits on contracts in progress
|
3,835 | 2,469 | ||||||
Other
current assets
|
4,271 | 4,511 | ||||||
Total
current assets
|
98,414 | 112,999 | ||||||
Property
and equipment, net
|
4,949 | 5,423 | ||||||
Goodwill
|
13,612 | 13,612 | ||||||
Other
intangible assets, net
|
13,067 | 13,388 | ||||||
Other
long-term assets
|
3,391 | 3,614 | ||||||
Total
assets
|
$ | 133,433 | $ | 149,036 | ||||
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
||||||||
Current
liabilities:
|
||||||||
Accounts
payable
|
$ | 798 | $ | 2,298 | ||||
Unearned
contract revenue
|
834 | 3,678 | ||||||
Accrued
salary and bonus
|
4,250 | 5,640 | ||||||
Accrued
contract loss
|
8,131 | 10,021 | ||||||
Other
accrued expenses
|
6,899 | 9,723 | ||||||
Total
current liabilities
|
20,912 | 31,360 | ||||||
Long-term
liabilities
|
10,664 | 10,569 | ||||||
Total
liabilities
|
31,576 | 41,929 | ||||||
Commitments
and contingencies (Note 7)
|
||||||||
Stockholders’
equity:
|
||||||||
Preferred
stock, $.01 par value; 5,000,000 shares authorized, no
|
||||||||
shares
issued and outstanding
|
- | - | ||||||
Common
stock, $.01 par value; 100,000,000 shares authorized;
|
||||||||
15,281,160
and 15,272,704 shares issued, respectively;
|
||||||||
14,227,909
and 14,223,669 shares outstanding, respectively
|
153 | 153 | ||||||
Additional
paid-in capital
|
122,398 | 121,908 | ||||||
Accumulated
deficit
|
(7,158 | ) | (1,443 | ) | ||||
Accumulated
other comprehensive loss
|
(18 | ) | (16 | ) | ||||
Treasury
stock, at cost (1,053,251 and 1,049,035 shares,
respectively)
|
(13,518 | ) | (13,495 | ) | ||||
Total
stockholders' equity
|
101,857 | 107,107 | ||||||
Total
liabilities and stockholders' equity
|
$ | 133,433 | $ | 149,036 | ||||
The
accompanying notes are an integral part of these condensed consolidated
financial statements
|
PDI,
INC.
|
||||||||
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
||||||||
(in
thousands, except for per share data)
|
||||||||
Three
Months Ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
(unaudited)
|
(unaudited)
|
|||||||
Revenue,
net
|
$ | 23,531 | $ | 32,229 | ||||
Cost
of services
|
18,559 | 23,530 | ||||||
Gross
profit
|
4,972 | 8,699 | ||||||
Compensation
expense
|
6,293 | 6,133 | ||||||
Other
selling, general and administrative expenses
|
4,258 | 4,274 | ||||||
Total
operating expenses
|
10,551 | 10,407 | ||||||
Operating
loss
|
(5,579 | ) | (1,708 | ) | ||||
Other
income, net
|
103 | 1,150 | ||||||
Loss
before income tax
|
(5,476 | ) | (558 | ) | ||||
Provision
for income tax
|
239 | 502 | ||||||
Net
loss
|
$ | (5,715 | ) | $ | (1,060 | ) | ||
Loss
per share of common stock:
|
||||||||
Basic
|
$ | (0.40 | ) | $ | (0.07 | ) | ||
Diluted
|
(0.40 | ) | (0.07 | ) | ||||
$ | (0.40 | ) | $ | (0.07 | ) | |||
Weighted
average number of common shares and
|
||||||||
common
share equivalents outstanding:
|
||||||||
Basic
|
14,223 | 14,223 | ||||||
Diluted
|
14,223 | 14,223 | ||||||
The
accompanying notes are an integral part of these condensed consolidated
financial statements
|
PDI,
INC.
|
||||||||
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
||||||||
(in
thousands)
|
||||||||
Three
Months Ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
(unaudited)
|
(unaudited)
|
|||||||
Cash
Flows From Operating Activities
|
||||||||
Net
loss from operations
|
$ | (5,715 | ) | $ | (1,060 | ) | ||
Adjustments
to reconcile net loss to net cash
|
||||||||
provided
by operating activities:
|
||||||||
Depreciation
and amortization
|
799 | 1,354 | ||||||
Deferred
income taxes, net
|
83 | 82 | ||||||
Provision
for bad debt
|
7 | 8 | ||||||
Stock-based
compensation
|
490 | 325 | ||||||
Other
|
- | 25 | ||||||
Other
changes in assets and liabilities:
|
||||||||
Decrease
in accounts receivable
|
6,555 | 12,959 | ||||||
Increase
in unbilled costs
|
(1,366 | ) | (2,094 | ) | ||||
Increase
in other current assets
|
(1,358 | ) | (462 | ) | ||||
Decrease
in other long-term assets
|
1,814 | 175 | ||||||
Decrease
in accounts payable
|
(1,500 | ) | (1,336 | ) | ||||
Decrease
in unearned contract revenue
|
(2,844 | ) | (3,221 | ) | ||||
Decrease
in accrued salaries and bonus
|
(1,390 | ) | (2,305 | ) | ||||
Decreae
in accrued contract loss
|
(1,890 | ) | - | |||||
Decrease
in accrued liabilities
|
(2,813 | ) | (428 | ) | ||||
Increase
in long-term liabilities
|
12 | 22 | ||||||
Net
cash (used in) provided by operating activities
|
(9,116 | ) | 4,044 | |||||
Cash
Flows From Investing Activities
|
||||||||
(Purchases)
sales of short-term investments, net
|
- | (1,483 | ) | |||||
Purchase
of property and equipment
|
(4 | ) | (221 | ) | ||||
Net
cash used in investing activities
|
(4 | ) | (1,704 | ) | ||||
Cash
Flows From Financing Activities
|
||||||||
Cash
paid for repurchase of restricted shares
|
(23 | ) | - | |||||
Net
(decrease) increase in cash and cash equivalents
|
(9,143 | ) | 2,340 | |||||
Cash
and cash equivalents – beginning
|
90,074 | 99,185 | ||||||
Cash
and cash equivalents – ending
|
$ | 80,931 | $ | 101,525 | ||||
The
accompanying notes are an integral part of these condensed consolidated
financial statements
|
1.
|
BASIS
OF PRESENTATION:
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES:
|
Three
Months Ended
|
|||||||
March
31,
|
|||||||
2009
|
2008
|
||||||
Basic
weighted average number of
|
14,223 | 14,223 | |||||
of
common shares
|
|||||||
Potential
dilutive effect of stock-based awards
|
- | - | |||||
Diluted
weighted average number
|
|||||||
of
common shares
|
14,223 | 14,223 | |||||
March
31,
|
|||||||
2009
|
2008
|
||||||
Options
|
302 | 358 | |||||
Stock-settled
stock appreciation rights (SARs)
|
351 | 458 | |||||
Restricted
stock units
|
239 | - | |||||
Performance
contingent SARs
|
280 | - | |||||
1,172 | 816 | ||||||
3.
|
INVESTMENTS
IN MARKETABLE SECURITIES:
|
Maturing
|
Maturing
|
||||||||||||||||||||
after
1 year
|
after
1 year
|
||||||||||||||||||||
March
31,
|
within
|
through
|
December
31,
|
within
|
through
|
||||||||||||||||
2009
|
1
year
|
3
years
|
2008
|
1
year
|
3
years
|
||||||||||||||||
Investments
supporting letters of credit:
|
|||||||||||||||||||||
Cash/money
accounts
|
$ | 41 | $ | 41 | $ | - | $ | 733 | $ | 733 | $ | - | |||||||||
US
Treasury securities
|
2,753 | 1,716 | 1,037 | 2,043 | 1,000 | 1,043 | |||||||||||||||
Government
agency securities
|
2,854 | 500 | 2,354 | 3,071 | 500 | 2,571 | |||||||||||||||
Total
|
$ | 5,648 | $ | 2,257 | $ | 3,391 | $ | 5,847 | $ | 2,233 | $ | 3,614 | |||||||||
4.
|
GOODWILL
AND OTHER INTANGIBLE ASSETS:
|
As
of March 31, 2009
|
As
of December 31, 2008
|
||||||||||||||||||||||
Carrying
|
Accumulated
|
Carrying
|
Accumulated
|
||||||||||||||||||||
Amount
|
Amortization
|
Net
|
Amount
|
Amortization
|
Net
|
||||||||||||||||||
Covenant
not to compete
|
$ | 140 | $ | 128 | $ | 12 | $ | 140 | $ | 121 | $ | 19 | |||||||||||
Customer
relationships
|
16,300 | 4,981 | 11,319 | 16,300 | 4,709 | 11,591 | |||||||||||||||||
Corporate
tradename
|
2,500 | 764 | 1,736 | 2,500 | 722 | 1,778 | |||||||||||||||||
Total
|
$ | 18,940 | $ | 5,873 | $ | 13,067 | $ | 18,940 | $ | 5,552 | $ | 13,388 |
2009
|
2010
|
2011
|
2012
|
2013
|
||||
$ 1,272
|
$ 1,253
|
$ 1,253
|
$ 1,253
|
$ 1,253
|
||||
5.
|
FACILITIES
REALIGNMENT:
|
Sales
|
Marketing
|
|||||||||||
Services
|
Services
|
Total
|
||||||||||
Balance
as of December 31, 2008
|
$ | 192 | $ | 367 | $ | 559 | ||||||
Accretion
|
1 | 2 | 3 | |||||||||
Payments
|
(14 | ) | (29 | ) | (43 | ) | ||||||
Balance
as of March 31, 2009
|
$ | 179 | $ | 340 | $ | 519 |
6.
|
FAIR
VALUE MEASUREMENTS:
|
Fair
Value
|
|||||||||||||||||||
Carrying
|
Fair
|
Measurements
at March 31, 2009
|
|||||||||||||||||
Amount
|
Value
|
Level
1
|
Level
2
|
Level
3
|
|||||||||||||||
Available-for-sale
securities
|
$ | 146 | $ | 146 | $ | 146 | $ | - | $ | - | |||||||||
Held-to-maturity
securities
|
5,648 | 5,744 | 5,744 | - | - | ||||||||||||||
Total
|
$ | 5,794 | $ | 5,890 | $ | 5,890 | $ | - | $ | - |
7.
|
COMMITMENTS
AND CONTINGENCIES:
|
8.
|
OTHER
COMPREHENSIVE LOSS:
|
Three
Months Ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
Net
loss
|
$ | (5,715 | ) | $ | (1,060 | ) | ||
Other
comprehensive loss
|
||||||||
Unrealized
holding gain on
|
||||||||
available-for-sale
securities
|
(2 | ) | (31 | ) | ||||
Other
comprehensive loss
|
$ | (5,717 | ) | $ | (1,091 | ) |
9.
|
PRODUCT
COMMERCIALIZATION CONTRACT:
|
10.
|
STOCK-BASED
COMPENSATION:
|
11.
|
INCOME
TAXES:
|
Three
Months Ended
|
||||||||
March
31,
|
||||||||
2009
|
2008
|
|||||||
Income
tax expense
|
$ | 239 | $ | 502 | ||||
Effective
income tax rate
|
4.4 | % | 90.0 | % |
12.
|
SEGMENT
INFORMATION:
|
Sales
|
Marketing
|
Product
|
||||||||||||||
Services
|
Services
|
Commercialization
|
Consolidated
|
|||||||||||||
Three
months ended March 31, 2009:
|
||||||||||||||||
Revenue
|
$ | 20,494 | $ | 3,037 | $ | - | $ | 23,531 | ||||||||
Operating
loss
|
(2,818 | ) | (2,111 | ) | (650 | ) | (5,579 | ) | ||||||||
Capital
expenditures
|
- | 4 | - | 4 | ||||||||||||
Depreciation
expense
|
330 | 125 | 23 | 478 | ||||||||||||
Three
months ended March 31, 2008:
|
||||||||||||||||
Revenue
|
$ | 25,256 | $ | 6,973 | $ | - | $ | 32,229 | ||||||||
Operating
(loss) income
|
(1,777 | ) | 69 | - | (1,708 | ) | ||||||||||
Capital
expenditures
|
198 | 23 | - | 221 | ||||||||||||
Depreciation
expense
|
844 | 190 | - | 1,034 |
13.
|
SUBSEQUENT
EVENT - CONTRACT TERMINATION:
|
|
·
|
The
effects of the current worldwide economic and financial
crisis;
|
· | Changes in outsourcing trends or a reduction in promotional, marketing and sales expenditures in the pharmaceutical, biotechnology and life sciences industries; |
|
●
Early termination of a significant services contract or the loss of one or
more of our significant customers or a material reduction in service
revenues from such customers;
|
|
·
|
Our
ability to obtain additional funds in order to implement our business
model;
|
|
●
Our ability to successfully identify, complete and integrate any future
acquisitions and the effects of any such acquisitions on our ongoing
business;
|
|
·
|
Our
ability to meet performance goals in incentive-based arrangements with
customers;
|
|
·
|
Competition
in our industry;
|
|
·
|
Our
ability to attract and retain qualified sales representatives and other
key employees and management
personnel;
|
|
·
|
Product
liability claims against us;
|
|
●
Changes in laws and healthcare regulations applicable to our industry or
our, or our customers’, failure to comply with such laws and
regulations;
|
|
·
|
The
sufficiency of our insurance and self-insurance reserves to cover future
liabilities;
|
|
·
|
Our
ability to successfully develop and generate sufficient revenue from
product commercialization
opportunities;
|
|
·
|
Our
ability to increase our revenues and successfully manage the size of our
operations;
|
|
·
|
Volatility
of our stock price and fluctuations in our quarterly revenues and
earnings;
|
|
·
|
Failure
of, or significant interruption to, the operation of our information
technology and communication systems;
and
|
|
·
|
The
results of any future impairment testing for goodwill and other intangible
assets.
|
|
·
|
Sales
Services, which is comprised of the following business
units:
|
|
o
|
Performance
Sales Teams; and
|
|
o
|
Select
Access.
|
|
·
|
Marketing
Services, which is comprised of the following business
units:
|
|
o
|
Pharmakon;
|
|
o
|
TVG
Marketing Research and Consulting (TVG);
and
|
|
o
|
Vital
Issues in Medicine (VIM)®.
|
|
·
|
Product
Commercialization.
|
Three
Months Ended
|
|||
March
31,
|
|||
Operating
data
|
2009
|
2008
|
|
Revenue,
net
|
100.0%
|
100.0%
|
|
Cost
of services
|
78.9%
|
73.0%
|
|
Gross
profit
|
21.1%
|
27.0%
|
|
Compensation
expense
|
26.7%
|
19.0%
|
|
Other
selling, general and administrative expenses
|
18.1%
|
13.3%
|
|
Total
operating expenses
|
44.8%
|
32.3%
|
|
Operating
loss
|
(23.7%)
|
(5.3%)
|
|
Other
income, net
|
0.4%
|
3.6%
|
|
Loss
before income tax
|
(23.3%)
|
(1.7%)
|
|
Provision
for income tax
|
1.0%
|
1.6%
|
|
Net
loss
|
(24.3%)
|
(3.3%)
|
Revenue
(in thousands)
|
||||||||||||||||
Quarter
Ended
|
||||||||||||||||
March
31,
|
||||||||||||||||
2009
|
2008
|
Change
($)
|
Change
(%)
|
|||||||||||||
Sales
services
|
$ | 20,494 | $ | 25,256 | $ | (4,762 | ) | (18.9 | %) | |||||||
Marketing
services
|
3,037 | 6,973 | (3,936 | ) | (56.4 | %) | ||||||||||
Product
commercialization
|
- | - | - | - | ||||||||||||
Total
|
$ | 23,531 | $ | 32,229 | $ | (8,698 | ) | (27.0 | %) |
Cost
of services (in thousands)
|
||||||||||||||||
Quarter
Ended
|
||||||||||||||||
March
31,
|
||||||||||||||||
2009
|
2008
|
Change
($)
|
Change
(%)
|
|||||||||||||
Sales
services
|
$ | 16,855 | $ | 19,908 | $ | (3,053 | ) | (15.3 | %) | |||||||
Marketing
services
|
1,704 | 3,622 | (1,918 | ) | (53.0 | %) | ||||||||||
Product
commercialization
|
- | - | - | - | ||||||||||||
Total
|
$ | 18,559 | $ | 23,530 | $ | (4,971 | ) | (21.1 | %) |
Gross
profit (in thousands)
|
||||||||||||||||||||||||||||||||
Quarter
Ended
|
Sales
|
%
of
|
Marketing
|
%
of
|
Product
|
%
of
|
%
of
|
|||||||||||||||||||||||||
March
31,
|
services
|
sales
|
services
|
sales
|
commercialization
|
sales
|
Total
|
sales
|
||||||||||||||||||||||||
2009
|
$ | 3,639 | 17.8 | % | $ | 1,333 | 43.9 | % | $ | - | - | $ | 4,972 | 21.1 | % | |||||||||||||||||
2008
|
5,348 | 21.2 | % | 3,351 | 48.1 | % | - | - | 8,699 | 27.0 | % | |||||||||||||||||||||
Change
($)
|
$ | (1,709 | ) | $ | (2,018 | ) | $ | - | $ | (3,727 | ) |
Compensation
expense (in thousands)
|
||||||||||||||||||||||||||||||||
Quarter
Ended
|
Sales
|
%
of
|
Marketing
|
%
of
|
Product
|
%
of
|
%
of
|
|||||||||||||||||||||||||
March
31,
|
services
|
sales
|
services
|
sales
|
commercialization
|
sales
|
Total
|
sales
|
||||||||||||||||||||||||
2009
|
$ | 3,538 | 17.3 | % | $ | 2,381 | 78.4 | % | $ | 374 | - | $ | 6,293 | 26.7 | % | |||||||||||||||||
2008
|
3,810 | 15.1 | % | 2,323 | 33.3 | % | - | - | 6,133 | 19.0 | % | |||||||||||||||||||||
Change
($)
|
$ | (272 | ) | $ | 58 | $ | 374 | $ | 160 |
Other
selling, general and administrative expenses (in
thousands)
|
||||||||||||||||||||||||||||||||
Quarter
Ended
|
Sales
|
%
of
|
Marketing
|
%
of
|
Product
|
%
of
|
%
of
|
|||||||||||||||||||||||||
March
31,
|
services
|
sales
|
services
|
sales
|
commercialization
|
sales
|
Total
|
sales
|
||||||||||||||||||||||||
2009
|
$ | 2,919 | 14.2 | % | $ | 1,063 | 35.0 | % | $ | 276 | - | $ | 4,258 | 18.1 | % | |||||||||||||||||
2008
|
3,315 | 13.1 | % | 959 | 13.8 | % | - | - | 4,274 | 13.3 | % | |||||||||||||||||||||
Change
($)
|
$ | (396 | ) | $ | 104 | $ | 276 | $ | (16 | ) |
Exhibit
No.
|
Description
|
|
31.1
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002, filed herewith as Exhibit 31.1.
|
|
31.2
|
Certification
of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002, filed herewith as Exhibit 31.2.
|
|
32.1
|
Certification
of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith
as Exhibit 32.1.
|
|
32.2
|
Certification
of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith
as Exhibit 32.2.
|
Date: May
7, 2009
|
PDI,
Inc.
|
||
(Registrant)
|
|||
/s/
Nancy Lurker
|
|||
Nancy
Lurker
|
|||
Chief
Executive Officer
|
|||
/s/
Jeffrey E. Smith
|
|||
Jeffrey
E. Smith
|
|||
Chief
Financial Officer
|